Translational Development Acquisition Corp. (TDAC) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Translational Development Acquisition Corp. (TDAC:NASDAQ), powered by AI.

Current Price
$10.73
Sector
Financial Services
What is the Translational Development Acquisition Corp. stock price forecast?

Translational Development Acquisition Corp. is currently trading at $10.73. View real-time AI analysis on Alpha Lenz.

What is Translational Development Acquisition Corp. insider trading activity?

View the latest insider trading data for Translational Development Acquisition Corp. on Alpha Lenz.

What is Translational Development Acquisition Corp.'s P/E ratio?

View Translational Development Acquisition Corp.'s valuation metrics on Alpha Lenz.

Translational Development Acquisition Corp.

NASDAQ · TDAC
$10.73+0.00(+0.00%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Translational Development Acquisition Corp.'s future dividend policy...
Alpha Chat Insight

Translational Development Acquisition Corp.'s ROE is 3.7%. Explore profitability and growth together.

Ask for details

Company Overview

Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC) focused on identifying and merging with businesses in the biopharmaceutical and pharmaceutical industry sectors. Aiming to leverage and support the growth of novel life sciences enterprises, this SPAC is dedicated to facilitating strategic partnerships that can lead to innovation and advancement in drug development and healthcare solutions. Translational Development Acquisition Corp. primarily targets companies with promising research and development pipelines that have the potential to transform patient care and enhance therapeutic options. This acquisition entity plays a pivotal role in providing capital and market access for rising enterprises within the dynamic and evolving field of biotechnology and pharmaceuticals, emphasizing the importance of scientific progress and industry collaboration in addressing unmet medical needs.

CEOMr. Michael M. B. Hoffman J.D.
SectorFinancial Services
IndustryShell Companies
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
$0.00Revenue
0.00Shares Out
0Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

3.57%ROA
3.70%ROE
-0.53%ROIC

Financial Health

$29.79KCash & Cash Equivalents
$6.55MNet Debt
3.76%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Translational Development Acquisition Corp. (ticker: TDAC) is a company listed on NASDAQ in the Financial Services sector (Shell Companies).

The current price is $10.73 with a P/E ratio of -x and P/B of -x.

ROE is 3.70%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Translational Development Acquisition Corp. (TDAC) Stock Forecast 2026 $10.73 — Price, Financials & Analyst Targets | Alpha Lenz